1-acetoxy-3,6,6,9-tetramethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromene | 19825-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-acetoxy-3,6,6,9-tetramethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromene
• 英文别名: acetic acid-(3,6,6,9-tetramethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-yl ester)；Essigsaeure-(3,6,6,9-tetramethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ylester)；1-acetoxy-7,8,9,10-tetrahydro-3,6,6,9-tetramethyl-6H-dibenzo[ b,d]pyran；Pirnabine；(3,6,6,9-tetramethyl-7,8,9,10-tetrahydrobenzo[c]chromen-1-yl) acetate
• CAS: 19825-63-9
• 化学式: C₁₉H₂₄O₃
• 分子量: 300.398
• InChiKey: AADNQNOXNWEYHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-acetoxy-3,6,6,9-tetramethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromene 在 cerium (IV) ammonium nitrate 、 碳酸氢钠 作用下， 以 氯仿 、 溶剂黄146 为溶剂， 以120 mg. (14.2%)的产率得到1-acetoxy-7-oxo-7,8,9,10-tetrahydro-3,6,6,9-tetramethyl-6H-dibenzo[ b,d]pyran
  参考文献：
  名称：

  Oxo C-ring benzopyrans

  摘要：

  式子为 ##STR1## 的苯并吡喃类化合物，其中n表示0或1，R为1至20个碳原子的烷基，芳基-较低烷基或环烷基-较低烷基，R.sub.1为氢或 ##STR2## 其中R.sub.4为较低烷基，苯基，环烷基-较低烷基或芳基-较低烷基，R.sub.2为较低烷基，R.sub.3为氢或一或两个较低烷基基团，含有该化合物的制药组合物以及该化合物作为镇静剂和镇痛剂的用途。

  公开号：

  US04051152A1
• 作为产物：
  描述：

  1-Hydroxy-3,6,6,9-tetramethyl-7,8,9,10-tetrahydro-6H-dibenzopyran 在 乙酸酐 作用下， 以 吡啶 、 水 为溶剂， 生成 1-acetoxy-3,6,6,9-tetramethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromene
  参考文献：
  名称：

  Oxo C-ring benzopyrans

  摘要：

  式子为 ##STR1## 的苯并吡喃类化合物，其中n表示0或1，R为1至20个碳原子的烷基，芳基-较低烷基或环烷基-较低烷基，R.sub.1为氢或 ##STR2## 其中R.sub.4为较低烷基，苯基，环烷基-较低烷基或芳基-较低烷基，R.sub.2为较低烷基，R.sub.3为氢或一或两个较低烷基基团，含有该化合物的制药组合物以及该化合物作为镇静剂和镇痛剂的用途。

  公开号：

  US04051152A1

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• DHA-pharmaceutical agent conjugates
  申请人：Luitpold Pharmaceuticals, Inc.

  公开号：EP1466628A1

  公开（公告）日：2004-10-13

  The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

  本发明提供了顺式-二十二碳六烯酸的共轭物和用于治疗非中枢神经系统疾病的药剂。本发明还提供了将药剂选择性靶向所需组织的方法。
• Compostions and methods for treating chemosensory dysfunction
  申请人：CYRANO THERAPEUTICS, INC.

  公开号：US10206927B2

  公开（公告）日：2019-02-19

  The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

  本发明涉及一种检测鼻腔分泌物中生物物质的方法，以及在检测到生物物质后诊断疾病的方法，其中生物物质与呼吸道疾病无关。本发明还提供了在检测到生物物质和/或诊断出疾病后的疾病治疗方法。在某些实施例中，疾病是癌症、肝炎、嗅觉减退、味觉减退、糖尿病和麻风病。本发明还提供了一种用于诊断疾病的试剂盒。本发明包括分析鼻腔样本以检测生物物质的方法。特别是，收集鼻分泌物或鼻涕并分析其中的生物物质。分析结果适用于诊断、预后和确定治疗干预的适宜性。
• Device and method for sustained release of low water solubility therapeutic agent in solubilizer
  申请人：NANOMEDICAL SYSTEMS, INC.

  公开号：US10369340B2

  公开（公告）日：2019-08-06

  Devices and methods for administering a therapeutic agent, including an implantable delivery device. Exemplary embodiments include a reservoir in fluid communication with a channeled member, and a compound including the therapeutic agent and a solubilizer disposed within the reservoir.

  用于施用治疗剂的设备和方法，包括一种植入式给药装置。示例性实施方案包括一个与通道部件流体相通的储液器，以及一个放置在储液器中的包括治疗剂和增溶剂的化合物。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。